Propranolol (PPN) is widely used in children to treat various cardiovascular diseases. The availability of a suitable PPN solution should avoid recourse to extemporaneous Preparations of unknown/limited stability, as commonly made in hospital pharmacies. However, the development of pediatric PPN solutions is hindered by their instability to light and stability at pH 3, bitter taste, and the need to improve palatability and avoid co-solvents, flavoring agents, or preservatives that are potentially toxic. In this study, Cyclodextrin (CD) complexation has been exploited to develop a safe, stable, and palatable oral pediatric solution of PPN. An initial screening among various CDs allowed us to select HPB CD for its good complexing ability and no toxicity. Drug-HPB CD physical mixtures or co-ground systems (1:1 or 1:2 mol:mol) were used to prepare 0.2% w/v drug solutions. Photo stability studies evidenced the protective effect of HPB CD, revealing a reduction of up to 75% in the drug degradation rate after 1 h of exposure to UV radiation. Storage stability studies showed unchanged physical–chemical properties and almost constant drug concentration after 6 months and under accelerated conditions (40°C), despite the less aggressive pH (5.5) of the solution. The electronic tongue test proved that the HP CD taste-masking properties improved the formulation palatability, with a 30% reduction in drug bitterness
Development of a Hydroxypropyl-beta -Cyclodextrin-based liquid formulation for the oral administration of propranolol in pediatric therapy / Marzia Cirri, Paola Mura, Simona Benedetti, Susanna Buratti. - In: PHARMACEUTICS. - ISSN 1999-4923. - ELETTRONICO. - 15:(2023), pp. 2217-2232. [10.3390/pharmaceutics15092217]
Development of a Hydroxypropyl-beta -Cyclodextrin-based liquid formulation for the oral administration of propranolol in pediatric therapy
Marzia Cirri
;Paola Mura;
2023
Abstract
Propranolol (PPN) is widely used in children to treat various cardiovascular diseases. The availability of a suitable PPN solution should avoid recourse to extemporaneous Preparations of unknown/limited stability, as commonly made in hospital pharmacies. However, the development of pediatric PPN solutions is hindered by their instability to light and stability at pH 3, bitter taste, and the need to improve palatability and avoid co-solvents, flavoring agents, or preservatives that are potentially toxic. In this study, Cyclodextrin (CD) complexation has been exploited to develop a safe, stable, and palatable oral pediatric solution of PPN. An initial screening among various CDs allowed us to select HPB CD for its good complexing ability and no toxicity. Drug-HPB CD physical mixtures or co-ground systems (1:1 or 1:2 mol:mol) were used to prepare 0.2% w/v drug solutions. Photo stability studies evidenced the protective effect of HPB CD, revealing a reduction of up to 75% in the drug degradation rate after 1 h of exposure to UV radiation. Storage stability studies showed unchanged physical–chemical properties and almost constant drug concentration after 6 months and under accelerated conditions (40°C), despite the less aggressive pH (5.5) of the solution. The electronic tongue test proved that the HP CD taste-masking properties improved the formulation palatability, with a 30% reduction in drug bitternessFile | Dimensione | Formato | |
---|---|---|---|
82_development_HPBCD liquid oral propr_ped_2023.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
3.21 MB
Formato
Adobe PDF
|
3.21 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.